A new understanding of the disease points to a target for creating drugs slowing disease progression.
The new method from the Baran lab is already having an impact on drug discovery programs.
Targeting a receptor called GPR158 may offer relief for major depressive disorder.
The breakthrough may expand research on the roles of glycans in human diseases, including cancers.